TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01561456
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
Study: NCT05127018
Drug: injection of Botulinum type A
Normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
Study: NCT01965158
Drug: Naldemedine
Normalized name: Naldemedine
DrugBank: Naldemedine (DB11691)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Naldemedine 0.2 mg tablet taken orally once a day
Study: NCT01305746
Drug: A-623
Normalized name: Padimate A
DrugBank: Padimate A (DB11229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
Study: NCT01305746
Drug: A-623
Normalized name: Padimate A
DrugBank: Padimate A (DB11229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
Study: NCT01305746
Drug: A-623
Normalized name: Padimate A
DrugBank: Padimate A (DB11229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
Study: NCT01829893
Drug: In combination of 0.2mg finasteride and 5mg tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral medication with 240 mL water
Study: NCT03055546
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal administration of oxytocin
Study: NCT03682198
Drug: Phenylephrine's effect on brain oxygenation
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.
Study: NCT03682198
Drug: Normal vs. high inspired oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
Study: NCT00569010
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days
Study: NCT00569010
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)
Study: NCT00356759
Drug: Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
Study: NCT02275013
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04860856
Drug: 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.
Study: NCT01547221
Drug: clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single application of 1%clotrimazole ear drop
Study: NCT01547221
Drug: 3% Boric acid
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
Study: NCT02783053
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin vs no metformin
Study: NCT00460317
Drug: AMG 706
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg QD orally every day
Study: NCT00605566
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally.
Study: NCT00460317
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
Study: NCT00460317
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
Study: NCT00826228
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: teriparatide 20ug daily sc for 6 months
Study: NCT02893488
Drug: EPZICOM (ABC/3TC)
Normalized name: Epzicom
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side.
Study: NCT02893488
Drug: TIVICAY (DTG)
Normalized name: Tivicay
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TIVICAY will be available as white, round, biconvex tablets
Study: NCT00585871
Drug: clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mg tid
Study: NCT00585871
Drug: metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tid
Study: NCT02104505
Drug: Gamma Tocopherol 700 mg capsules,
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules daily
Study: NCT03912974
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see 'arm description'
Study: NCT02899364
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see description under experimental arm
Study: NCT02899364
Drug: Sodium chloride 0.9%
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see description under placebo comparator arm
Study: NCT03321006
Drug: Duloxetine or escitalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
Study: NCT03486925
Drug: oxytocin treatment
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal administration of oxytocin (24IU)
Study: NCT00885352
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg tablet orally once daily for 26 weeks.
Study: NCT03282981
Drug: Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical application of Timolol on non-healing diabetic foot ulcers
Study: NCT03282981
Drug: Non biologically active gel
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
Study: NCT00885352
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
Study: NCT00885352
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
Study: NCT04325009
Drug: Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab
Study: NCT04325009
Drug: Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Lipitor 80mg Tab
Study: NCT00207402
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infergen 15mcg/ d Avandia qd Ribavirin bid
Study: NCT02397343
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01181609
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
Study: NCT00687245
Drug: esomeprazole magnesium
Normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules, oral, qd, one day
Study: NCT02330276
Drug: (+)-Epicatechin
Normalized name: (+)-Epicatechin
DrugBank: Epicatechin (DB12039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
Study: NCT03953456
Drug: elafibranor 120mg
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: elafibranor 120mg is a coated tablet for oral administration, once daily
Study: NCT05683912
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal aflibercept as used in the routice clinical practice
Study: NCT00180089
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04486508
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statin
Study: NCT00885352
Drug: Glipizide
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
Study: NCT03232710
Drug: abilify
Normalized name: Abilify
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazol orodispersible tablets 10mg
Study: NCT00511836
Drug: VIVITROL 380 mg
Normalized name: Vivitrol 380 MG Injection
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
Study: NCT00632385
Drug: Eletriptan
Normalized name: Eletriptan
DrugBank: Eletriptan (DB00216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred \>2 hours from first dose and within 24 hours of first dose
Study: NCT02457442
Drug: SPR 1
Normalized name: betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision.
Study: NCT02354547
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
Study: NCT04418661
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion
Study: NCT03490617
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
Study: NCT04418661
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Sterile Tablet Route of administration: Oral
Study: NCT00239096
Drug: losartan (drug)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03871621
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin tablet (10 mg)
Study: NCT03282136
Drug: Incretin Effect
Normalized name: Secretin
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will receive incretins therapy.
Study: NCT03177109
Drug: Self-adhesive resin
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically as a coating at single point in time and light cured for 20 seconds
Study: NCT00412880
Drug: BI 2536
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT04059887
Drug: Atezolizumab Injection [Tecentriq]
Normalized name: atezolizumab Injection [Tecentriq]
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
Study: NCT01397500
Drug: Genotropin
Normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin administered sc once a day by patient or caregiver.
Study: NCT01085812
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
Study: NCT01168336
Drug: Betahistine standard formulation
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: betahistine 24 mg tablets
Study: NCT01168336
Drug: Betahistine Extended Release formulation
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: betahistine 32 mg tablets
Study: NCT00237354
Drug: PV-10 (rose bengal disodium 10%)
Normalized name: PV
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PV-10 ablation of study lesion
Study: NCT00003912
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003912
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01799109
Drug: Magnesium Sulfate & albuterol
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01799109
Drug: albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01799109
Drug: magnesium
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03520062
Drug: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Normalized name: LIRAGLUTIDE (SAXENDA) 6MG/ML INJ PEN 3ML
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Liraglutide (3.0mg per day) for \~6 weeks
Study: NCT00165334
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00165334
Drug: Vinorelbine (Navelbine)
Normalized name: vinorelbine Injection [Navelbine]
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00941642
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
Study: NCT02181907
Drug: UH-AC 62 XX tablet
Normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181907
Drug: UH-AC 62 XX capsule
Normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02735590
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
Study: NCT02735590
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine based on body weight (\>32kg - 50kg: 750 mg; \>50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
Study: NCT02934945
Drug: budesonide 160μg/formoterol 4.5μg
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SMART regimen
Study: NCT00713674
Drug: mupirocin antibiotic ointment
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mupirocin antibiotic ointment swab intranasal BID for 5 days
Study: NCT00192023
Drug: atomoxetine 0.5 mg/kg/day
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
Study: NCT03707847
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250mg, BID, PO
Study: NCT03707847
Drug: Etoposide Capsule
Normalized name: Etoposide Capsules
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg, QD, PO, d1-10，21days for one cycle
Study: NCT02134366
Drug: Clobazam
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of AED use in Epilepsia Partialis Continua
Study: NCT02134366
Drug: Clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of AED use in Epilepsia Partialis Continua
Study: NCT02134366
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of AED use in Epilepsia Partialis Continua
Study: NCT00365274
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given 1.4 mg/m\^2 IV